Your browser doesn't support javascript.
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
Bracken, Colton J; Lim, Shion A; Solomon, Paige; Rettko, Nicholas J; Nguyen, Duy P; Zha, Beth Shoshana; Schaefer, Kaitlin; Byrnes, James R; Zhou, Jie; Lui, Irene; Liu, Jia; Pance, Katarina; Zhou, Xin X; Leung, Kevin K; Wells, James A.
  • Bracken CJ; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Lim SA; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Solomon P; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Rettko NJ; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Nguyen DP; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Zha BS; Lyell Immunopharma Inc., Seattle, WA, USA.
  • Schaefer K; Department of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Byrnes JR; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Zhou J; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Lui I; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Liu J; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Pance K; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Zhou XX; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Wells JA; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Nat Chem Biol ; 17(1): 113-121, 2021 01.
Article in English | MEDLINE | ID: covidwho-882912
ABSTRACT
Neutralizing agents against SARS-CoV-2 are urgently needed for the treatment and prophylaxis of COVID-19. Here, we present a strategy to rapidly identify and assemble synthetic human variable heavy (VH) domains toward neutralizing epitopes. We constructed a VH-phage library and targeted the angiotensin-converting enzyme 2 (ACE2) binding interface of the SARS-CoV-2 Spike receptor-binding domain (Spike-RBD). Using a masked selection approach, we identified VH binders to two non-overlapping epitopes and further assembled these into multivalent and bi-paratopic formats. These VH constructs showed increased affinity to Spike (up to 600-fold) and neutralization potency (up to 1,400-fold) on pseudotyped SARS-CoV-2 virus when compared to standalone VH domains. The most potent binder, a trivalent VH, neutralized authentic SARS-CoV-2 with a half-maximal inhibitory concentration (IC50) of 4.0 nM (180 ng ml-1). A cryo-EM structure of the trivalent VH bound to Spike shows each VH domain engaging an RBD at the ACE2 binding site, confirming our original design strategy.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Single-Chain Antibodies / Spike Glycoprotein, Coronavirus / Angiotensin-Converting Enzyme 2 / Antibodies, Viral Type of study: Randomized controlled trials Limits: Animals / Humans Language: English Journal: Nat Chem Biol Journal subject: Biology / Chemistry Year: 2021 Document Type: Article Affiliation country: S41589-020-00679-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Single-Chain Antibodies / Spike Glycoprotein, Coronavirus / Angiotensin-Converting Enzyme 2 / Antibodies, Viral Type of study: Randomized controlled trials Limits: Animals / Humans Language: English Journal: Nat Chem Biol Journal subject: Biology / Chemistry Year: 2021 Document Type: Article Affiliation country: S41589-020-00679-1